Replicel Life Sciences Inc V.RP

Alternate Symbol(s): REPCF

Healthcare Biotechnology

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.

TSXV:RP - Post by User

Replicel Life Sciences Inc

Bullboard Posts

Comment by lv_426on Mar 11, 2020 1:15pm

54 Views

Post# 30794055

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:WHERE DO WE GO FROM HERE

psvbruceleefc wrote: and something tells me the dermal injector is gonna play a large part in getting Shiseido and Replicel talking again, they need it for comercialisaton

The dermal injector is the perfect fit for RCH01 but its months away from being on the market. Another thought, shiseido says more testing. Wonder if they mean now its replicel time to run a trial....that would mean at least three more years before commercialization

Bullboard Posts

A Look into the Future of Chronic Pain Management